Disease · MONDO_0005077
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| dTpa Group vs Control Group: Number of Subjects With Unsolicited Adverse Events (AEs) | 94 of 263 | 111 of 277 | 540 | NCT02853929 | Trial comparisons |
| dTpa Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs) | 0 of 263 | 3 of 277 | 540 | NCT02853929 | Trial comparisons |
| dTpa Group vs Control Group: deaths from any cause | 0 of 263 | 0 of 277 | 540 | NCT02853929 | Trial comparisons |
| dTpa Group vs Control Group: serious adverse events | 0 of 263 | 3 of 277 | 540 | NCT02853929 | Trial comparisons |
| 6th Dose Pertussis Vaccine Group vs 5th Dose Pertussis Vaccine Group: serious adverse events | 0 of 117 | 0 of 98 | 215 | NCT00304265 | Trial comparisons |
| Tralokinumab vs Placebo: Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 | 33 of 106 | 21 of 108 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16. | 52 of 106 | 39 of 108 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: deaths from any cause | 1 of 107 | 0 of 107 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: serious adverse events | 3 of 107 | 3 of 107 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: Positive Anti-tetanus Response at Week 16 | 80 of 87 | 73 of 76 | 163 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: Positive Anti-meningococcal Response at Week 16 | 74 of 86 | 64 of 76 | 162 | NCT03562377 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005077/comparisons